Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Despite the approval of protease inhibitors Telaprevir and Boceprevir and the increased SVR rates observed in GT 1 infected patients, new compounds are needed to achieve higher cure rates, shorten duration of treatment and reduce side-effects. Emergence of resistance continues to be a key factor limiting antiviral efficacy and is therefore an important parameter to control for in clinical trials. Understanding the nature of the resistance mechanism(s), natural prevalence of resistant mutants and their fitness and persistence will allow a better design of treatment options. Nucleos(t)ide analogues present a high barrier to resistance, pangenotypic activity and are not cross resistant to other direct acting antivirals which make them good candidates for combination therapy for the treatment of hepatitis.
Infectious Diseases Discovery, Hoffmann-La Roche, Grenzacherstrasse 124, Basel 4070, Switzerland. Electronic address: isabel.najera@roche.com.
Isabel
I
Najera
D000818:Animals; D016174:Hepacivirus / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D009705:Nucleosides / Q000737:chemistry / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D014764:Viral Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
D009705:Nucleosides; D011480:Protease Inhibitors; D014764:Viral Proteins; D012324:RNA-Dependent RNA Polymerase